Phosphorus-32 - UW-L Brachy CoursePhosphorus-32 - UW-L Brachy CoursePhosphorus-32 - UW-L Brachy Course
Student Spotlight - Site Templates


Relevant historical data: 1934-Hilde Levi and George Charles von Hevlesy prepared he first radiocative isotope of phosporus.
1942-Dr. Kenne administered by mouth and by injection P-32 on 27 cases of adults suffering form leukemia.
Chemical/Radioactive Composition: Na2H32PO4 32S+1 32P+1H
16 on 15 1
Energy Characteristics: Maximum energy of 1.7 MeV. Average or mean 0.7 MeV.
Exposure Rate Constant: P-32 is a pure beta emitter. Has no exposure rate constant.
Half-life Properties: 14.3 days
Forms available for use: Sodium Phospate (soluble phospate) and Chromic Phospate
HVL in lead: 0.02 mmPb
Measurement/Calibrations/QA: Seprachorm Chromatogram, or activity can be measured in a dose calibrater.
Used in formula/calculation: D= 3,000mCi/70,000 g x 0.7 x 14.3 days = 31.7 cGy This is the dose given for a patient weighing 70,000 grams.
Uses in Radiation Oncology: Used to treat polycythemia vera, to alleviate bone pain from breast and prostate ca, post-op for ovarian ca, malignant effusions, and now is to treat patients with grade 4 glioblastoma multiforme,
Treatment Planning: No planning is done due P-32 being a beta emitter.
One other interesting fact: It is interesting that in 1942 P-32 was administered in an attempt to cure leukemia. In subsequent years, due to large radiation dose to the bone marrow from P-32 injection for polycythemia vera leukemia was reported in several patients. The drug thought to cure leukemia in some cases actually caused it.


References: Purdy, James A. Advances in Radiation Oncology Physics. Woodbury, New York: American Institute of Physics, Inc., 1992.

Selman, Joseph. The Basic Physics of Radiation Therapy. Springfield Illinois: Bannerstone House Pulblishing, 1976.

More pages